Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Acrux Limited ( (AU:ACR) ).
Acrux Limited announced an update regarding the proposed issue of securities, reducing the maximum number of options to 163,957,905 following the completion of their Share Purchase Plan on 18 December 2024. An extraordinary general meeting is scheduled for 3 February 2025 to seek shareholder approval under listing rules 7.1 and 10.11, impacting the company’s future strategic plans and shareholder engagement.
More about Acrux Limited
Acrux Limited operates in the pharmaceutical industry, focusing on the development and commercialization of innovative transdermal and topical drug delivery systems. The company targets both local and international markets with its proprietary technology.
YTD Price Performance: 10.0%
Average Trading Volume: 3,250
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $7.74M
See more data about ACR stock on TipRanks’ Stock Analysis page.
